TROJANIELLO, CLAUDIA
TROJANIELLO, CLAUDIA
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
2024 Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am.
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
2024 Hepner, A; Versluis, Jm; Wallace, R; Allayous, C; Brown, Lj; Trojaniello, C; Gerard, Cl; Jansen, Yj; Bhave, P; Neyns, B; Haydon, A; Michielin, O; Mangana, J; Klein, O; Shoushtari, An; Warner, Ab; Ascierto, Pa; Mcquade, Jl; Carlino, Ms; Zimmer, L; Lebbe, C; Johnson, Db; Sandhu, S; Atkinson, V; Blank, Cu; Lo, Sn; Long, Gv; Menzies, Am
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
2023 Mallardo, D; Simeone, E; Festino, L; Tuffanelli, M; Vanella, V; Trojaniello, C; Vitale, Mg; Ottaviano, M; Capone, M; Madonna, G; Sparano, F; Cioli, E; Scarpato, L; Palla, M; Di Trolio, R; Meinardi, P; Caracò, C; Ferrara, G; Muto, P; Cavalcanti, E; Ascierto, Pa.
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
2023 Trojaniello, C; Sparano, F; Cioli, E; Ascierto, Pa
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
2023 Weppler, Am; Da Meda, L; Pires Da Silva, I; Xu, W; Grignani, G; Menzies, Am; Carlino, Ms; Long, Gv; Lo, Sn; Nordman, I; Steer, Cb; Lyle, M; Trojaniello, C; Ascierto, Pa; Lebbe, C; Sandhu, S.
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
2023 Ascierto, Pa; Cioli, E; Chiarion-Sileni, V; Quaglino, P; Spagnolo, F; Guidoboni, M; Del Vecchio, M; Peris, K; Queirolo, P; Fioretto, L; Caracò, C; Paone, M; Sorrentino, A; Capone, M; Giannarelli, D; Ferrara, G; Massi, D; Trojaniello, C
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy | 1.1 Articolo in rivista | 2024 | Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am. | |
| The features and management of acquired resistance to PD1-based therapy in metastatic melanoma | 1.1 Articolo in rivista | 2024 | Hepner, A; Versluis, Jm; Wallace, R; Allayous, C; Brown, Lj; Trojaniello, C; Gerard, Cl; Jansen, Yj; Bhave, P; Neyns, B; Haydon, A; Michielin, O; Mangana, J; Klein, O; Shoushtari, An; Warner, Ab; Ascierto, Pa; Mcquade, Jl; Carlino, Ms; Zimmer, L; Lebbe, C; Johnson, Db; Sandhu, S; Atkinson, V; Blank, Cu; Lo, Sn; Long, Gv; Menzies, Am | |
| IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab | 1.1 Articolo in rivista | 2023 | Mallardo, D; Simeone, E; Festino, L; Tuffanelli, M; Vanella, V; Trojaniello, C; Vitale, Mg; Ottaviano, M; Capone, M; Madonna, G; Sparano, F; Cioli, E; Scarpato, L; Palla, M; Di Trolio, R; Meinardi, P; Caracò, C; Ferrara, G; Muto, P; Cavalcanti, E; Ascierto, Pa. | |
| Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned | 1.1 Articolo in rivista | 2023 | Trojaniello, C; Sparano, F; Cioli, E; Ascierto, Pa | |
| Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation | 1.1 Articolo in rivista | 2023 | Weppler, Am; Da Meda, L; Pires Da Silva, I; Xu, W; Grignani, G; Menzies, Am; Carlino, Ms; Long, Gv; Lo, Sn; Nordman, I; Steer, Cb; Lyle, M; Trojaniello, C; Ascierto, Pa; Lebbe, C; Sandhu, S. | |
| Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study | 1.1 Articolo in rivista | 2023 | Ascierto, Pa; Cioli, E; Chiarion-Sileni, V; Quaglino, P; Spagnolo, F; Guidoboni, M; Del Vecchio, M; Peris, K; Queirolo, P; Fioretto, L; Caracò, C; Paone, M; Sorrentino, A; Capone, M; Giannarelli, D; Ferrara, G; Massi, D; Trojaniello, C |